On January 9, the Jiangsu Provincial Drug Administration showedMedlander (688273.SH) obtains medical device registration certificate for its brain-computer interface transcranial magnetic stimulator, becoming the first company in Jiangsu Province to receive a certificate for a non-invasive brain-computer interface related product.According to the investor relations record disclosed by the company on December 24, 2025, after the registration certificate for the brain-computer interface transcranial magnetic stimulator is obtained, this technology will be quickly integrated into the company's existing product lines, such as the soft hand function training system and pelvic floor rehabilitation equipment, achieving large-scale application of technological achievements. This not only marks an important breakthrough for Medlander in the field of cutting-edge medical technology but also signifies a substantive step forward in the industrial application of non-invasive brain-computer interfaces. It also opens up new opportunities for the company’s future technological expansion and performance growth.

Data shows,This product is equipped with two core modules: magnetic stimulation and brain-computer interface. Among them, the magnetic stimulation module can stimulate the central and peripheral nerves of the human body.Used for the detection, evaluation, and improvement of central and peripheral nervous system (including pelvic floor) functions in the human body, as well as for the auxiliary treatment of nerve injury diseases and lumbosacral nerve dysfunction. The brain-computer module is used to monitor physiological parameters such as hemoglobin concentration changes in response to cerebral hemodynamics and electroencephalographic signals, displaying brain status data through dynamic imaging.

Medlander has actively promoted business transformation and technological iteration in recent years,Not only has it established a solid revenue base in niche medical device fields such as pelvic floor rehabilitation and reproductive rehabilitation, but it has also clearly laid out a strategic roadmap for advanced medical technology directions, including brain-computer interfaces.The company's previously released research data shows that its brain-computer interface product focuses on non-invasive multimodal technology (combining EEG and fNIRS signals) to enhance clinical usability and signal analysis accuracy. It was projected to obtain the first brain-computer interface medical device registration certificate in the first quarter of 2026. The actual acquisition of the certificate this time has preliminarily validated the effectiveness of this strategic layout, further accelerating the integration of the technology into the existing rehabilitation product line.

Brain-computer interface technology is entering a critical phase of accelerated commercialization and clinical application. Driven by national policy support, the establishment of industry standards, and continuous breakthroughs in core technologies, the brain-computer interface industry chain is advancing from the research validation stage toward large-scale market expansion.The domestic market scale is growing rapidly, with technology routes including invasive, semi-invasive, and non-invasive methods developing in parallel, indicating that this field is expected to achieve multi-scenario integrated development in medical treatment, rehabilitation, and consumer applications in the future.

Medlander not only possesses mature R&D and production capabilities for medical devices but has also accumulated extensive experience in information technology and intelligent diagnosis and treatment systems. This will facilitate the integrated advancement of product iteration and market promotion in high-tech fields such as brain-computer interfaces. Additionally, collaborations with research institutions and the introduction of cutting-edge technologies have strongly supported the company in strengthening its technical barriers and establishing clinical trust. The recent acquisition of Jiangsu Province's first non-invasive brain-computer interface product registration certificate holds significant strategic importance and market potential, offering clear long-term benefits to the company’s development.